318 related articles for article (PubMed ID: 32969580)
1. D-Dimer Enhances Risk-Targeted Thromboprophylaxis in Ambulatory Patients with Cancer.
Kumar V; Shaw JR; Key NS; Ilich A; Mallick R; Wells PS; Carrier M
Oncologist; 2020 Dec; 25(12):1075-1083. PubMed ID: 32969580
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial.
Wang TF; Mallick R; Carrier M; Wells PS
Thromb Res; 2022 Mar; 211():85-87. PubMed ID: 35124234
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial.
Brandt W; Brown C; Wang TF; Tagalakis V; Shivakumar S; Ciuffini LA; Mallick R; Wells PS; Carrier M
Thromb Res; 2022 Aug; 216():8-10. PubMed ID: 35660801
[TBL] [Abstract][Full Text] [Related]
4. Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial.
Kimpton M; Wells PS; Carrier M
Thromb Res; 2018 Apr; 164 Suppl 1():S124-S129. PubMed ID: 29703470
[TBL] [Abstract][Full Text] [Related]
5. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Carrier M; Abou-Nassar K; Mallick R; Tagalakis V; Shivakumar S; Schattner A; Kuruvilla P; Hill D; Spadafora S; Marquis K; Trinkaus M; Tomiak A; Lee AYY; Gross PL; Lazo-Langner A; El-Maraghi R; Goss G; Le Gal G; Stewart D; Ramsay T; Rodger M; Witham D; Wells PS;
N Engl J Med; 2019 Feb; 380(8):711-719. PubMed ID: 30511879
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA
Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379
[TBL] [Abstract][Full Text] [Related]
7. Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: Insights from the AVERT trial.
Potere N; Di Nisio M; Porreca E; Wang TF; Tagalakis V; Shivakumar S; Delluc A; Mallick R; Wells PS; Carrier M
Thromb Res; 2023 Jun; 226():82-85. PubMed ID: 37121015
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial.
Knoll W; Mallick R; Wells PS; Carrier M
Thromb Res; 2021 Jan; 197():13-15. PubMed ID: 33160115
[TBL] [Abstract][Full Text] [Related]
9. Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer.
Shaw JR; Kumar V; Mallick R; Carrier M; Ilich A; Key NS; Wells P
Thromb Res; 2020 Dec; 196():437-443. PubMed ID: 33065408
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: A post-hoc analysis of the AVERT trial.
Ladha D; Mallick R; Wang TF; Caiano L; Wells PS; Carrier M
Thromb Res; 2021 Jun; 202():151-154. PubMed ID: 33857789
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of primary prevention of venous thromboembolism among subgroups of cancer patients undergoing chemotherapy: A post- hoc analysis of the AVERT trial.
Nayak AL; Zahrai A; Mallick R; Wang TF; Delluc A; Castellucci LA; Carrier M; Wells PS
Thromb Res; 2021 Dec; 208():79-82. PubMed ID: 34742140
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer.
Kimpton M; Kumar S; Wells PS; Coyle D; Carrier M; Thavorn K
CMAJ; 2021 Oct; 193(40):E1551-E1560. PubMed ID: 35040802
[TBL] [Abstract][Full Text] [Related]
13. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.
Artifoni M; Danic G; Gautier G; Gicquel P; Boutoille D; Raffi F; Néel A; Lecomte R
J Thromb Thrombolysis; 2020 Jul; 50(1):211-216. PubMed ID: 32451823
[TBL] [Abstract][Full Text] [Related]
14. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
Khorana AA; Francis CW; Kuderer NM; Carrier M; Ortel TL; Wun T; Rubens D; Hobbs S; Iyer R; Peterson D; Baran A; Kaproth-Joslin K; Lyman GH
Thromb Res; 2017 Mar; 151():89-95. PubMed ID: 28139259
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients.
Schorling RM; Pfrepper C; Golombek T; Cella CA; Muñoz-Unceta N; Siegemund R; Engel C; Petros S; Lordick F; Knödler M
Oncol Res Treat; 2020; 43(9):414-427. PubMed ID: 32580190
[TBL] [Abstract][Full Text] [Related]
16. Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis.
Bosch FTM; Mulder FI; Kamphuisen PW; Middeldorp S; Bossuyt PM; Büller HR; van Es N
Blood Adv; 2020 Oct; 4(20):5215-5225. PubMed ID: 33104795
[TBL] [Abstract][Full Text] [Related]
17. Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial.
Zhang J; Atalla M; Mallick R; Wells PS; Carrier M
J Thromb Thrombolysis; 2021 Apr; 51(3):720-724. PubMed ID: 33079379
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of apixaban and rivaroxaban in thromboprophylaxis of cancer patients treated with chemotherapy in Spain.
Muñoz AJ; Ortega L; Gutiérrez A; Gallardo E; Rubio-Rodríguez D; Rubio-Terrés C; Morón B; García-Alfonso P; Soria JM
J Med Econ; 2023; 26(1):1145-1154. PubMed ID: 37602646
[TBL] [Abstract][Full Text] [Related]
19. [Thromboprophylaxis in ambulatory patients with cancer].
Hart C; Heudobler D; Linnemann B
Dtsch Med Wochenschr; 2020 Feb; 145(3):130-134. PubMed ID: 32018283
[TBL] [Abstract][Full Text] [Related]
20. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
Wang Y; Wang M; Ni Y; Liang Z
Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
[No Abstract] [Full Text] [Related]
[Next] [New Search]
